Results 81 to 90 of about 26,623 (217)

Lessons from a BACE1 inhibitor trial: off-site but not off base [PDF]

, 2014
Alzheimer's disease (AD) is characterized by formation of neuritic plaque primarily composed of a small filamentous protein called amyloid-β peptide (Aβ). The rate-limiting step in the production of Aβ is the processing of Aβ precursor protein (APP) by β-
Greig, Nigel H., Lahiri, Debomoy K., Long, Justin M., Maloney, Bryan   +3 more
core   +1 more source

Beyond the neuron: Exosomes as intercellular modulators of mitochondrial networks in the pathogenesis and treatment of Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by β‐amyloid deposition, hyperphosphorylated tau protein, and progressive neuronal loss. Mitochondria form a dynamic interconnected network within the central nervous system, and their dysfunction plays a central role in AD, involving oxidative stress, kinetic ...
Liping Xing, Annan Liu, Wei Gao, Jianhui Li, Mingyuan Yao, Jing Song, Peihan Duan, Honglin Li   +7 more
wiley   +1 more source

Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025)

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract Alzheimer's disease (AD) continues to pose a major public health challenge. Since its launch in 2004, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has played a pivotal role in advancing the field by providing a comprehensive, open‐access, longitudinal dataset that integrates neuroimaging, biomarker, genetic, and clinical data related
Shaveta Kanoria, Dallas P. Veitch, Melanie J. Miller, Paul S. Aisen, Laurel A. Beckett, Robert C. Green, Danielle J. Harvey, Clifford R. Jack Jr., William Jagust, Edward B. Lee, Kwangsik Nho, Rachel Nosheny, Ozioma C. Okonkwo, Richard J. Perrin, Ronald C. Petersen, Monica Rivera Mindt, Andrew J. Saykin, Leslie M. Shaw, Arthur W. Toga, Duygu Tosun, Susan M. Landau, Michael W. Weiner, for the Alzheimer's Disease Neuroimaging Initiative   +22 more
wiley   +1 more source

Serum Starvation Induces BACE1 Processing and Secretion

Current Alzheimer Research, 2017
Background: β-secretase (BACE1) is a type 1 transmembrane protein implicated in Alzheimer’s Disease (AD) pathogenesis. Cleavage of Amyloid Precursor Protein (APP), initiated by BACE1 and followed by γ-secretase, leads to the formation of toxic Aβ peptides.
Stavropoulou, A.V., Mavrofrydi, O., Saftig, P., Efthimiopoulos, S.   +3 more
openaire   +3 more sources

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease [PDF]

, 2010
The BACE1 gene encodes the beta-site APP-cleaving enzyme 1 and has been associated with Alzheimer's disease (AD). BACE1 is the most important beta-secretase responsible for the generation of Alzheimer-associated amyloid beta-proteins (A beta) and may ...
Annica Sjölander, Henrik Zetterberg, Ulf Andreasson, Lennart Minthon, Kaj Blennow   +4 more
core   +2 more sources

Human iPSC‐derived GABAergic interneuron transplantation restores circuit balance and cognitive function in an Alzheimer's disease model

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) is characterized by disrupted excitatory–inhibitory (E:I) balance and impaired synaptic function, yet current treatments fail to repair these fundamental circuit impairments. METHODS Human induced pluripotent stem cell‐derived post‐mitotic medial ganglionic eminence‐originated inhibitory neurons (MGE‐pINs)
Xinzhe Zhang, Gaojie Wang, Haodong Chen, Ye Sun, Ziteng Wangliu, Lijing Wang, Miao Sun, Qing Liu, Xue Zhang   +8 more
wiley   +1 more source

BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease

Brain Research Bulletin
While the β-secretase BACE1 is responsible for the rate-limiting initial step to generate amyloid-β (Aβ) peptides, BACE1 inhibitor clinical trials have been halted due to a lack of efficacy and/or safety concerns at symptomatic/prodromal stages of ...
Masuo Ohno
doaj   +1 more source

Mitochondria and the Actin Cytoskeleton in Neurodegeneration

Cytoskeleton, Volume 83, Issue 4, Page 200-210, April 2026.
ABSTRACT Mitochondrial dysfunction and cytoskeletal disorganization are widely recognized hallmarks of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
Shivani Tuli, Preet Patel, Aneri Shethji, David Gau   +3 more
wiley   +1 more source

High-temperature mechanical behavior of polycrystalline yttrium-doped barium cerate perovskite [PDF]

, 2011
The high-temperature mechanical properties of the mixed ionic-electronic conductor perovskite BaCe0.95Y0.05O3-δ with average grain size of 0.40μm have been studied in compression between 1100 and 1300°C in air at different initial strain rates.
Jiménez Melendo, Manuel, López Robledo, Manuel Jesús, Martínez Fernández, Julián, Real Pérez, Concepción, Vaquero Aguilar, Cristina   +4 more
core   +1 more source

AS1842856 Reduces β‐Amyloid Burden via Inhibiting PLA2G4A‐Mediated Lysosomal Dysfunction in APP/PS1 Mice

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
AS1842856 reduces intracellular levels of GSK3α/β by binding to them and promoting their exocytosis. This reduction leads to diminished GSK3β‐mediated activation of NF‐κB, resulting in decreased transcription of PLA2G4A and reduced lysosomal damage. Ultimately, this enhances lysosomal degradation of Aβ, lowering Aβ load in APP/PS1 mice.
Da‐Long He, Zheng Wu, Rong‐Jun Jia, Ting‐Yao Wu, Yi‐Min Qiu, Yong‐Gang Fan   +5 more
wiley   +1 more source